These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 9488184)

  • 1. The etiology of benign prostatic hypertrophy.
    Roper WG
    Med Hypotheses; 1998 Jan; 50(1):61-5. PubMed ID: 9488184
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The prevention of benign prostatic hyperplasia (bph).
    Roper WG
    Med Hypotheses; 2017 Mar; 100():4-9. PubMed ID: 28236846
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Benign prostatic hyperplasia: a review of its histogenesis and natural history.
    Oesterling JE
    Prostate Suppl; 1996; 6():67-73. PubMed ID: 8630233
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Etiology and disease process of benign prostatic hyperplasia.
    Isaacs JT; Coffey DS
    Prostate Suppl; 1989; 2():33-50. PubMed ID: 2482772
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship of neuroendocrine cells of prostate and serotonin to benign prostatic hyperplasia.
    Cockett AT; di Sant'Agnese PA; Gopinath P; Schoen SR; Abrahamsson PA
    Urology; 1993 Nov; 42(5):512-9. PubMed ID: 7694415
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Epidemiology and natural course of benign prostatic hyperplasia].
    Blom JH; Schröder FH
    Urologe A; 1992 May; 31(3):129-34. PubMed ID: 1377429
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The controversial relationship between benign prostatic hyperplasia and prostate cancer: the role of inflammation.
    De Nunzio C; Kramer G; Marberger M; Montironi R; Nelson W; Schröder F; Sciarra A; Tubaro A
    Eur Urol; 2011 Jul; 60(1):106-17. PubMed ID: 21497433
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Benign hypertrophy of the prostate: pathogenic aspects].
    Páez Borda A; Fernández Lucas C; Diego García A; Prieto Chaparro L; Gómez Ruiz JJ; Rapariz González M; Silmi Moyano A; Salinas Casado J; Blázquez Izquierdo J; Usón Calvo A
    Arch Esp Urol; 1991 Apr; 44(3):229-36. PubMed ID: 1714264
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostate development and growth in benign prostatic hyperplasia.
    Timms BG; Hofkamp LE
    Differentiation; 2011; 82(4-5):173-83. PubMed ID: 21939815
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Etiology of benign prostatic hyperplasia.
    Isaacs JT
    Eur Urol; 1994; 25 Suppl 1():6-9. PubMed ID: 7507055
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chronic inflammation in the pathogenesis of benign prostatic hyperplasia.
    Fibbi B; Penna G; Morelli A; Adorini L; Maggi M
    Int J Androl; 2010 Jun; 33(3):475-88. PubMed ID: 19508330
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Physiopathological aspects of the treatment of benign prostatic hypertrophy. Role of prostatic stroma and estrogens].
    Solè-Balcells F
    J Urol (Paris); 1993; 99(6):303-6. PubMed ID: 7516373
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of growth factors in benign prostatic hyperplasia.
    Lawson RK
    Eur Urol; 1997; 32 Suppl 1():22-7. PubMed ID: 9218939
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hyperinsulinaemia as a risk factor for developing benign prostatic hyperplasia.
    Hammarsten J; Högstedt B
    Eur Urol; 2001 Feb; 39(2):151-8. PubMed ID: 11223674
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Histological changes of the prostate and acute urinary retention in patients with benign prostatic hyperplasia].
    Bao QB; He GH; Liu GY; Zhang CG; Yang C
    Zhonghua Nan Ke Xue; 2013 Sep; 19(9):811-4. PubMed ID: 24386860
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vascular resistance in the prostate evaluated by colour Doppler ultrasonography: is benign prostatic hyperplasia a vascular disease?
    Berger AP; Horninger W; Bektic J; Pelzer A; Spranger R; Bartsch G; Frauscher F
    BJU Int; 2006 Sep; 98(3):587-90. PubMed ID: 16796699
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vascular damage induced by type 2 diabetes mellitus as a risk factor for benign prostatic hyperplasia.
    Berger AP; Deibl M; Halpern EJ; Lechleitner M; Bektic J; Horninger W; Fritsche G; Steiner H; Pelzer A; Bartsch G; Frauscher F
    Diabetologia; 2005 Apr; 48(4):784-9. PubMed ID: 15756540
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insulin-resistance and benign prostatic hyperplasia: the connection.
    Vikram A; Jena G; Ramarao P
    Eur J Pharmacol; 2010 Sep; 641(2-3):75-81. PubMed ID: 20553919
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and experimental studies of benign prostatic hyperplasia.
    Coffey DS; Walsh PC
    Urol Clin North Am; 1990 Aug; 17(3):461-75. PubMed ID: 1695775
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Testosterone and Benign Prostatic Hyperplasia.
    Rastrelli G; Vignozzi L; Corona G; Maggi M
    Sex Med Rev; 2019 Apr; 7(2):259-271. PubMed ID: 30803920
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.